Glenmark Life zooms 9%, hits 52-week high after Q4 results

Glenmark Life Science’s Q4 profit jumped 48% YoY to Rs146 crore, while revenue from operations rose 21% YoY to Rs621 crore. Its EBITDA grew 45.2% YoY to Rs206.4 crore with 33.2% margins YoY, benefiting from high CDMO contribution, better product mix, PLI scheme benefit, and lower input costs. The company’s generic API revenues rose 15% YoY. Glenmark Life is a leading manufacturer of high-value, non-commoditised APIs. The stock has surged 23% YTD and 37% in the last month trading at Rs516 on BSE.